Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412

Dayan, Colin Mark ORCID: https://orcid.org/0000-0002-6557-3462 and Wraith, D. C. 2008. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clinical and Experimental Immunology 151 (2) , pp. 231-234. 10.1111/j.1365-2249.2007.03559.x

Full text not available from this repository.

Abstract

Current immunology research is generating many new approaches to immunotherapy. However, the recent disaster surrounding the testing of TGN1412, has unsettled regulators and the pharmaceutical industry regarding new immunotherapies and highlighted the complexities of conducting clinical trials with agents that target the immune system. Here we discuss the critical role for immunologists in ensuring that the development of new immunotherapies continues.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > R Medicine (General)
Uncontrolled Keywords:	clinical trials, first-in-man, immunotherapy, phase 1, TGN1412
Publisher:	Wiley-Blackwell
ISSN:	0009-9104
Last Modified:	20 Oct 2022 07:45
URI:	https://orca.cardiff.ac.uk/id/eprint/26279

Citation Data

Cited 29 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item